Related Experiment Videos
Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients
Insights
High lipoprotein(a) [Lp(a)] levels independently predict coronary artery disease (CAD) death risk in hemodialysis (HD) patients. This finding highlights Lp(a) as a crucial biomarker for cardiovascular events in this population.
Area of Science:
- Nephrology
- Cardiology
- Biomarkers
Background:
- Cardiovascular disease (CAD) is a major concern for patients undergoing hemodialysis (HD).
- Lipoprotein(a) [Lp(a)] is a potential risk factor for CAD.
- The independent role of Lp(a) in predicting CAD mortality in HD patients requires further investigation.
Purpose of the Study:
- To determine if serum lipoprotein(a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD) mortality.
- To assess the association between Lp(a) levels and cardiovascular events in hemodialysis (HD) patients.
Main Methods:
- Serum Lp(a) concentrations were measured in 268 HD patients (212 with chronic glomerulonephritis, 56 with diabetic nephropathy).
- Patients were followed for five years to track causes of death, categorized as cardiovascular or noncardiovascular events.
Main Results:
- Overall mortality in the HD cohort was 26.1%, with 78% attributed to cardiovascular events.
- Patients who died from cardiovascular events exhibited significantly higher serum Lp(a) levels compared to those with noncardiovascular deaths.
- A Lp(a) concentration above 30 mg/dl was associated with a relative risk of 0.71 for death from CAD.
Conclusions:
- Serum Lp(a) levels serve as independent indicators of future risk for CAD-related death in hemodialysis patients.
- Elevated Lp(a) may be a valuable biomarker for stratifying cardiovascular risk in the HD population.
Background:
We studied whether lipoprotein(a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD) in hemodialysis (HD) patients.
Methods:
A serum concentration of Lp(a) was measured in 212 patients with chronic glomerulonephritis and 56 patients with diabetic nephropathy (a total of 268 patients). The causes of death during five years of follow-up were studied and classified into either cardiovascular or noncardiovascular events.
Results:
The mortality of these 268 HD patients during the observation period was 26.1%. Seventy-eight percent were due to cardiovascular events. Those who died of cardiovascular events had significantly higher serum Lp(a) levels than those died of noncardiovascular events. The relative risk of death from CAD was 0.71 in HD patients with a Lp(a) concentration above 30 mg/dl.
Conclusions:
This study indicates that the serum Lp(a) levels are independent indicators of the future risk of death from CAD in HD patients.